S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
NASDAQ:RPRX

Royalty Pharma (RPRX) Stock Price, News & Analysis

$29.93
-0.41 (-1.35%)
(As of 03/1/2024 ET)
Today's Range
$29.69
$30.47
50-Day Range
$27.24
$31.33
52-Week Range
$25.92
$38.19
Volume
2.68 million shs
Average Volume
3.51 million shs
Market Capitalization
$17.88 billion
P/E Ratio
15.84
Dividend Yield
2.81%
Price Target
$52.25

Royalty Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
74.6% Upside
$52.25 Price Target
Short Interest
Bearish
3.04% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
1.32mentions of Royalty Pharma in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$8.86 M Sold Last Quarter
Proj. Earnings Growth
9.65%
From $3.73 to $4.09 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.99 out of 5 stars

Finance Sector

3rd out of 854 stocks

Pharmaceutical Preparations Industry

2nd out of 424 stocks


RPRX stock logo

About Royalty Pharma Stock (NASDAQ:RPRX)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

RPRX Stock Price History

RPRX Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Goldman Sachs Reaffirms Their Buy Rating on Royalty Pharma (RPRX)
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
Royalty Pharma Reports Q4 and Full Year 2023 Results
Royalty Pharma Reports Q4 and Full Year 2023 Results
Royalty Pharma's Earnings: A Preview
Royalty Pharma Plc (RPRX)
What Makes Royalty Pharma plc (RPRX) a Compelling Stock?
See More Headlines
Receive RPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Ex-Dividend for 12/15 Dividend
11/16/2023
Dividend Payable
12/15/2023
Ex-Dividend for 3/15 Dividend
2/15/2024
Today
3/02/2024
Dividend Payable
3/15/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Finance
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:RPRX
CUSIP
76028H20
Fax
N/A
Employees
51
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$52.25
High Stock Price Target
$60.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+74.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$1.13 billion
Pretax Margin
72.20%

Debt

Sales & Book Value

Annual Sales
$2.36 billion
Cash Flow
$4.51 per share
Book Value
$16.88 per share

Miscellaneous

Free Float
485,595,000
Market Cap
$17.88 billion
Optionable
Optionable
Beta
0.45

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Pablo Gerardo Legorreta (Age 59)
    Founder, Chairman of the Board & CEO
  • Mr. Terrance P. Coyne
    Executive VP & CFO
  • Mr. George Wingate Lloyd (Age 65)
    Executive VP of Investments & Chief Legal Officer
    Comp: $4.35M
  • Mr. Christopher Hite (Age 57)
    Vice Chairman & Executive VP
    Comp: $4.35M
  • Dr. Marshall Urist M.D.
    Ph.D., Executive VP and Head of Research & Investments
  • Mr. Arthur R. McGivern J.D.
    Executive Vice President of Investments & General Counsel
  • Mr. Ashwin Pai M.D.
    Executive Vice President of Investments
  • Mr. Eric Schneider
    Senior VP & Chief Technology Officer
  • Dr. James Folmar Reddoch Ph.D. (Age 54)
    Executive VP of Investments & Chief Scientific Officer
    Comp: $3.4M
  • Mr. George Grofik C.F.A.
    CPA, Senior VP and Head of Investor Relations & Communications














RPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Royalty Pharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RPRX shares.
View RPRX analyst ratings
or view top-rated stocks.

What is Royalty Pharma's stock price target for 2024?

4 analysts have issued 1-year target prices for Royalty Pharma's stock. Their RPRX share price targets range from $42.00 to $60.00. On average, they anticipate the company's share price to reach $52.25 in the next twelve months. This suggests a possible upside of 74.6% from the stock's current price.
View analysts price targets for RPRX
or view top-rated stocks among Wall Street analysts.

How have RPRX shares performed in 2024?

Royalty Pharma's stock was trading at $28.09 at the beginning of 2024. Since then, RPRX stock has increased by 6.6% and is now trading at $29.93.
View the best growth stocks for 2024 here
.

When is Royalty Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RPRX earnings forecast
.

How were Royalty Pharma's earnings last quarter?

Royalty Pharma plc (NASDAQ:RPRX) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by $0.52. The biopharmaceutical company earned $587 million during the quarter, compared to analysts' expectations of $568.92 million. Royalty Pharma had a trailing twelve-month return on equity of 26.93% and a net margin of 48.22%. During the same period last year, the company posted $0.48 earnings per share.

How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma?

Royalty Pharma declared a quarterly dividend on Friday, January 19th. Investors of record on Friday, February 16th will be paid a dividend of $0.21 per share on Friday, March 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.81%. The ex-dividend date of this dividend is Thursday, February 15th. This is a boost from the stock's previous quarterly dividend of $0.20.
Read our dividend analysis for RPRX
.

Is Royalty Pharma a good dividend stock?

Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.84 per share and currently has a dividend yield of 2.74%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RPRX will have a dividend payout ratio of 20.54% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RPRX.

What other stocks do shareholders of Royalty Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO).

When did Royalty Pharma IPO?

(RPRX) raised $1.9 billion in an initial public offering (IPO) on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.

Who are Royalty Pharma's major shareholders?

Royalty Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.36%), Baillie Gifford & Co. (2.94%), Viking Global Investors LP (1.69%), Norges Bank (0.71%), Legal & General Group Plc (0.49%) and Goldman Sachs Group Inc. (0.48%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Avara Management Ltd, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Sanjay Kumar Singh, Scientific Corp Boston and Terrance P Coyne.
View institutional ownership trends
.

How do I buy shares of Royalty Pharma?

Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RPRX) was last updated on 3/2/2024 by MarketBeat.com Staff